|
Market Closed -
Nasdaq
23:00:00 08/09/2026 +03
|
5-day change | 1st Jan Change | ||
| 212.50 USD | -3.77% |
|
-1.64% | +20.75% |
| 09-08 | Dyne, Sarepta shares tumble as Novartis setback weighs on muscle disease drug developers | RE |
| 09-04 | Eisai, Biogen Secure China's Nod for Self-Injection Version of Leqembi | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Biopharmaceuticals
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 31.4B | |||||
| 80.91B | |||||
| 60.46B | |||||
| 56.02B | - | ||||
| 49.63B | |||||
| 45.88B |
- Stock Market
- Stocks
- BIIB Stock
- Charts Biogen Inc.
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
